{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-138242","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2024-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.425216+00:00","generated_at":"2026-05-29T01:26:22.194613+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Assembly Bio receives $10M from Gilead, Gilead buys 940,499 shares at $21.37","bullets":["Gilead pays $10M upfront payment creditable against future collaboration obligations.","Opt-in fees for ABI-6250 restructured; total aggregate payments unchanged.","Gilead purchases 940,499 shares at $21.37/share, a 35% premium to 30-day VWAP.","Amendment redefines Phase 1b clinical trial and Triggering Clinical Trial for certain programs.","Additional Funding Payment of $10M due within [***] days; use restricted per Section 15.5(a)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-138242","json":"https://secwatch.observer/filing/0000950170-24-138242.json","markdown":"https://secwatch.observer/filing/0000950170-24-138242.md","text":"https://secwatch.observer/filing/0000950170-24-138242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000095017024138242/0000950170-24-138242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000095017024138242/asmb-20241219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T01:26:22.194613+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}